Ke-37,
PF-382,
TALL-1,
HPB-ALL,
DND-41,
MOLT-4,
JURKAT,
p12-ichikawa and ALL-SIL were purchased by DSMZ.
CCRF-CEM cell lines was obtained by ATCC.
Ke-37,
PF-382,
TALL-1,
DND-41, ALL-SIL,
CCRF-CEM,
MOLT-4,
JURKAT,
p12-ichikawa were cultured in
RPMI-1640 (Gibco, Life Technologies, Carlsbad, California, USA), supplemented with 10%
fetal bovine serum (Lonza Group, Basel, Switzerland), 100 U/mL
penicillin and 100 mg/mL
streptomycin (Gibco, Life Technologies), and maintained at 37°C in a 5% CO
2 atmosphere.
HPB-ALL cell line was cultured in
RPMI-1640 supplemented with 20%
fetal bovine serum.
Caracciolo D., Riillo C., Ballerini A., Gaipa G., Lhermitte L., Rossi M., Botta C., Duroyon E., Grillone K., Gallo Cantafio M.E., Buracchi C., Alampi G., Gulino A., Belmonte B., Conforti F., Golino G., Juli G., Altomare E., Polerà N., Scionti F., Arbitrio M., Iannone M., Martino M., Correale P., Talarico G., Ghelli Luserna di Rorà A., Ferrari A., Concolino D., Sestito S., Pensabene L., Giordano A., Hildinger M., Di Martino M.T., Martinelli G., Tripodo C., Asnafi V., Biondi A., Tagliaferri P, & Tassone P. (2021). Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. Journal for Immunotherapy of Cancer, 9(2), e002026.